Based on a pooled popPK analysis that included data from patients with RET-altered thyroid cancers, patients with RET-fusion NSCLC and healthy subjects in different pralsetinib studies, disease status does not have a clinically relevant impact on the PK of pralsetinib [3]. Here, RET is linked to thyroid gland carcinoma.